Logo Logo
Switch Language to German

Lim, Yen Ying; Maruff, Paul; Barthelemy, Nicolas R.; Goate, Alison; Hassenstab, Jason; Sato, Chihiro; Fagan, Anne M.; Benzinger, Tammie L. S.; Xiong, Chengjie; Cruchaga, Carlos; Levin, Johannes; Farlow, Martin R.; Graff-Radford, Neill R.; Laske, Christoph; Masters, Colin L.; Salloway, Stephen; Schofield, Peter R.; Morris, John C.; Bateman, Randall J. and McDade, Eric (2022): Association of BDNF Val66Met With Tau Hyperphosphorylation and Cognition in Dominantly Inherited Alzheimer Disease. In: JAMA Neurology, Vol. 79, No. 3: pp. 261-270

Full text not available from 'Open Access LMU'.


IMPORTANCE Allelic variation in the brain-derived neurotrophic factor (BDNF) Val66Met polymorphism moderates increases in cerebrospinal fluid (CSF) levels of tau and phosphorylated tau 181 (p-tau181), measured using immunoassay, and cognitive decline in presymptomatic dominantly inherited Alzheimer disease (DIAD). Advances in mass spectrometry show that CSF tau phosphorylation occupancy at threonine 181 and 217 (p-tau181/tau181, p-tau217/tau217) increases with initial beta-amyloid (A beta) aggregation, while phosphorylation occupancy at threonine 205 (p-tau205/tau205) and level of total tau increase when brain atrophy and clinical symptoms become evident. OBJECTIVE To determine whether site-specific tau phosphorylation occupancy (ratio of phosphorylated to unphosphorylated tau) is associated with BDNF Val66Met in presymptomatic and symptomatic DIAD. DESIGN, SETTING, AND PARTICIPANTS This cross-sectional cohort study included participants from the Dominantly Inherited Alzheimer Network (DIAN) and A beta-positive cognitively normal older adults in the Alzheimer's Disease Neuroimaging Initiative (ADNI). Data were collected from 2009 through 2018 at multicenter clinical sites in the United States, United Kingdom, and Australia, with no follow-up. DIAN participants provided a CSF sample and completed clinical and cognitive assessments. Data analysis was conducted between March 2020 and March 2021. MAIN OUTCOMES AND MEASURES Mass spectrometry analysis was used to determine site-specific tau phosphorylation level;tau levels were also measured using immunoassay. Episodic memory and global cognitive composites were computed. RESULTS Of 374 study participants, 144 were mutation noncarriers, 156 were presymptomatic mutation carriers, and 74 were symptomatic carriers. Of the 527 participants in the network, 153 were excluded because their CSF sample, BDNF status, or both were unavailable. Also included were 125 A beta-positive cognitively normal older adults in the ADNI. The mean (SD) age of DIAD participants was 38.7 (10.9) years;43% were women. The mean (SD) age of participants with preclinical sporadic AD was 74.8 (5.6) years;52% were women. In presymptomatic mutation carriers, compared with Val66 homozygotes, Met66 carriers showed significantly poorer episodic memory (d = 0.62;95% CI, 0.28-0.95), lower hippocampal volume (d = 0.40;95% CI, 0.09-0.71), and higher p-tau217/tau217 (d = 0.64;95% CI, 0.30-0.97), p-tau181/tau181 (d = 0.65;95% CI, 0.32-0.99), and mass spectrometry total tau (d = 0.43;95% CI, 0.10-0.76). In symptomatic mutation carriers, Met66 carriers showed significantly poorer global cognition (d = 1.17;95% CI, 0.65-1.66) and higher p-tau217/tau217 (d = 0.53;95% CI. 0.05-1.01), mass spectrometry total tau (d = 0.78;95% CI, 0.28-1.25), and p-tau205/tau205 (d = 0.97: 95% CI, 0.46-1.45), when compared with Val66 homozygotes. In preclinical sporadic AD, Met66 carriers showed poorer episodic memory (d = 0.39;95% CI, 0.00-0.77) and higher total tau (d = 0.45;95% CI, 0.07-0.84) and p-tau181 (d = 0.46;95% CI, 0.07-0.85). CONCLUSIONS AND RELEVANCE In DIAD, clinical disease stage and BDNF Met66 were associated with cognitive impairment and levels of site-specific tau phosphorylation. This suggests that pharmacological strategies designed to increase neurotrophic support in the presymptomatic stages of AD may be beneficial.

Actions (login required)

View Item View Item